There is limited experience with overdose of LINZESS. During the clinical development program of LINZESS, single doses of 2897 mcg were administered to 22 healthy volunteers; the safety profile in these subjects was consistent with that in the overall LINZESS-treated population, with diarrhea being the most commonly reported adverse reaction.
LINZESS is contraindicated in:
- Pediatric patients under 6 years of age [see WARNINGS AND PRECAUTIONS, Use In Specific Populations and Nonclinical Toxicology]
- Patients with known or suspected mechanical gastrointestinal obstruction
Last reviewed on RxList: 7/25/2014
This monograph has been modified to include the generic and brand name in many instances.
Additional Linzess Information
Report Problems to the Food and Drug Administration
Get the latest treatment options.